Targeting Immunological Restrainers: Understanding the Immunology Behind Combination Chemoimmunotherapy to Improve the Treatment of Malignant Mesothelioma
Abstract
This study looks at the role the body s immune system plays during mesothelioma tumour development with a specific focus on a subset of immune cells called Treg that act to limit anti-tumour immunity. Our preliminary studies indicated that a number or previously published inhibitors of Treg cells are not effective in our models. We employed a new animal model which allows for the depletion of Treg cells in a very controlled manner and observed that targeted removal of Treg, particularly during early tumour development can significantly enhance anti-tumour immunity and delay tumour development. We are currently investigating whether Treg removal in combination with chemotherapy can improve survival outcomes relative to individual therapies. Additionally, we have observed that asbestos induced mesothelioma development is slower in mice that lack a functional immune system compared to mice that are immune competent. Experiments are currently underway to establish the immunological mechanisms behind these interesting findings. On completion of this study we will have a greater understanding of the role host immunity plays during early stages of tumour development and subsequent treatment of established tumours and will use this information to develop improved therapies for the treatment of malignant mesothelioma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA600732
Entities
People
- Bruce H. Robinson
- Cleo Robinson
- Scott Fisher
Organizations
- University of Western Australia